Use of telomerase reverse transcriptase for treatment of conditions associated with myocardial infarction

The inventors have found that the vectors of the invention are useful in the treatment of myocardial infarction, for example, in tissue damage resulting from myocardial infarction, fibrosis of the myocardium resulting from myocardial infarction, and reducing cardiac function resulting from myocardial infarction. Using non-integrative viral vectors, such as AAV, seems to be particularly advantageous. For example, non-integrative vectors do not cause any permanent genetic modification; the vectors target to adult tissues, avoiding having the subjects under the effect of constitutive telomerase expression from early stages of development, and additionally, non-integrative vectors.